Skin tumors Rb(eing) uncovered

Frontiers in Oncology

Volumn 3 DEC, Issue , 2013, Pages

  Costa, Clotilde ^a   Paramio, Jesús M ^a   Santos, Mirentxu ^a  

^a CIEMAT   (Spain)

Author keywords

E2F; Epidermis; p107; p130; p53; pRb; SCC; Transgenic mice

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; CYCLIN DEPENDENT KINASE; DNA METHYLTRANSFERASE; HETEROCHROMATIN PROTEIN 1; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; MICRORNA; PROTEIN P107; PROTEIN P130; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTOR E2F;

CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; GENOMIC INSTABILITY; NONHUMAN; PHENOTYPE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RB1 GENE; REVIEW; SKIN TUMOR; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 84892408975     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00307     Document Type: Review

References (171)

1. Capecchi MR. Targeted gene replacement. Sci Am (1994) 270(3):52-9. doi: 10.1038/scientificamerican0394-52.
2. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis (2000) 26(2):99-109. doi:10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.3.CO;2-2.
3. Berns A. Tumour suppressors: timing will tell. Nature (2003) 424(6945):140-1. doi:10.1038/424140a.
4. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res (1995) 23(10):1686-90. doi:10.1093/nar/23.10.1686.
5. Ramirez A, Bravo A, Jorcano JL, Vidal M. Sequences 5' of the bovine keratin 5 gene direct tissue-and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation (1994) 58(1):53-64. doi:10.1007/s002580050065.
6. Ramirez A, Vidal M, Bravo A, Larcher F, Jorcano JL. A 5'-upstream region of a bovine keratin 6 gene confers tissue-specific expression and hyperproliferation-related induction in transgenic mice. Proc Natl Acad Sci U S A (1995) 92(11):4783-7. doi:10.1073/pnas.92.11.4783.
7. Sinha S, Fuchs E. Identification and dissection of an enhancer controlling epithelial gene expression in skin. Proc Natl Acad Sci U S A (2001) 98(5):2455-60. doi:10.1073/pnas.051633598.
8. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet (2001) 29(4):418-25. doi:10.1038/ng747.
9. Vasioukhin V, Degenstein L, Wise B, Fuchs E. The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci U S A (1999) 96(15):8551-6. doi:10.1073/pnas.96.15.8551.
10. Fuchs E, Merrill BJ, Jamora C, DasGupta R. At the roots of a never-ending cycle. Dev Cell (2001) 1(1):13-25. doi:10.1016/S1534-5807(01)00022-3.
11. Watt FM. Stem cell fate and patterning in mammalian epidermis. Curr Opin Genet Dev (2001) 11(4):410-7.
12. Alonso L, Fuchs E. Stem cells of the skin epithelium. Proc Natl Acad Sci U S A (2003) 11:11.
13. Lorz C, Segrelles C, Paramio JM. On the origin of epidermal cancers. Curr Mol Med (2009) 9(3):353-64. doi:10.2174/156652409787847227.
14. Beck B, Blanpain C. Mechanisms regulating epidermal stem cells. EMBO J (2012) 31(9):2067-75. doi:10.1038/emboj.2012.67.
15. Blanpain C, Fuchs E. Epidermal stem cells of the skin. Annu Rev Cell Dev Biol (2006) 22:339-73. doi:10.1146/annurev.cellbio.22.010305.104357.
16. Lapouge G, Youssef KK, Vokaer B, Achouri Y, Michaux C, Sotiropoulou PA, et al. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci U S A (2012) 108(18):7431-6. doi:10.1073/pnas.1012720108.
17. da Silva-Diz V, Sole-Sanchez S, Valdes-Gutierrez A, Urpi M, Riba-Artes D, Penin RM, et al. Progeny of Lgr5-expressing hair follicle stem cell contributes to papillomavirus-induced tumor development in epidermis. Oncogene (2013) 32(32):3732-43. doi:10.1038/onc.2012.375.
18. Blanpain C, Lowry WE, Geoghegan A, Polak L, Fuchs E. Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. Cell (2004) 118(5):635-48. doi:10.1016/j.cell.2004.08.012.
19. Tumbar T, Guasch G, Greco V, Blanpain C, Lowry WE, Rendl M, et al. Defining the epithelial stem cell niche in skin. Science (2004) 303(5656):359-63. doi:10.1126/science.1092436.
20. Hennings H, Michael D, Cheng C, Steinert P, Holbrook K, Yuspa SH. Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell (1980) 19(1):245-54. doi:10.1016/0092-8674(80)90406-7.
21. Yuspa SH, Kilkenny AE, Steinert PM, Roop DR. Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations in vitro. J Cell Biol (1989) 109(3):1207-17. doi:10.1083/jcb.109.3.1207.
22. Llames SG, Del Rio M, Larcher F, Garcia E, Garcia M, Escamez MJ, et al. Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation (2004) 77(3):350-5. doi:10.1097/01.TP.0000112381.80964.85.
23. Del Rio M, Larcher F, Serrano F, Meana A, Munoz M, Garcia M, et al. A preclinical model for the analysis of genetically modified human skin in vivo. Hum Gene Ther (2002) 13(8):959-68. doi:10.1089/10430340252939069.
24. Buitrago-Perez A, Hachimi M, Duenas M, Lloveras B, Santos A, Holguin A, et al. A humanized mouse model of HPV-associated pathology driven by E7 expression. PLoS One (2012) 7(7):e41743. doi:10.1371/journal.pone.0041743.
25. Martinez-Cruz AB, Costa C, Saiz C, Paramio JM, Santos M. In vivo transplantation of genetically modified mouse embryonic epidermis. Methods Mol Biol (2010) 585:361-7. doi:10.1007/978-1-60761-380-0_25.
26. Slaga TJ, Budunova IV, Gimenez-Conti IB, Aldaz CM. The mouse skin carcinogenesis model. J Investig Dermatol Symp Proc (1996) 1(2):151-6.
27. Schwarz M, Munzel PA, Braeuning A. Non-melanoma skin cancer in mouse and man. Arch Toxicol (2012) 87(5):783-98. doi:10.1007/s00204-012-0998-9.
28. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature (1986) 323(6089):643-6. doi:10.1038/323643a0.
29. Ewen ME, Xing YG, Lawrence JB, Livingston DM. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell (1991) 66(6):1155-64. doi:10.1016/0092-8674(91)90038-Z.
30. Yeung RS, Bell DW, Testa JR, Mayol X, Baldi A, Grana X, et al. The retinoblastoma-related gene, RB2, maps to human chromosome 16q12 and rat chromosome 19. Oncogene (1993) 8(12):3465-8.
31. Mayol X, Grana X, Baldi A, Sang N, Hu Q, Giordano A. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene (1993) 8(9):2561-6.
32. Moran E. Interaction of adenoviral proteins with pRB and p53. FASEB J (1993) 7(10):880-5.
33. Chan HM, Smith L, La Thangue NB. Role of LXCXE motif-dependent interactions in the activity of the retinoblastoma protein. Oncogene (2001) 20(43):6152-63. doi:10.1038/sj.onc.1204793.
34. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell (1995) 81(3):323-30. doi:10.1016/0092-8674(95)90385-2.
35. Lamber EP, Beuron F, Morris EP, Svergun DI, Mittnacht S. Structural insights into the mechanism of phosphoregulation of the retinoblastoma protein. PLoS One (2013) 8(3):e58463. doi:10.1371/journal.pone.0058463.
36. Burke JR, Hura GL, Rubin SM. Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control. Genes Dev (2012) 26(11):1156-66. doi:10.1101/gad.189837.112.
37. Classon M, Dyson N. p107 and p130: versatile proteins with interesting pockets. Exp Cell Res (2001) 264(1):135-47. doi:10.1006/excr.2000.5135.
38. Ewen ME, Faha B, Harlow E, Livingston DM. Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science (1992) 255(5040):85-7. doi:10.1126/science.1532457.
39. Faha B, Ewen ME, Tsai LH, Livingston DM, Harlow E. Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science (1992) 255(5040):87-90. doi:10.1126/science.1532458.
40. Hannon GJ, Demetrick D, Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev (1993) 7(12A):2378-91. doi:10.1101/gad.7.12a.2378.
41. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 9(3):153-66. doi:10.1038/nrc2602.
42. Harper JW, Elledge SJ. Cdk inhibitors in development and cancer. Curr Opin Genet Dev (1996) 6(1):56-64.
43. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div (2013) 7(1):10. doi:10.1186/1747-1028-7-10.
44. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol (2013) 14(5):297-306. doi:10.1038/nrm3567.
45. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci (2004) 117(Pt 11):2173-81. doi:10.1242/jcs.01227.
46. McClellan KA, Slack RS. Specific in vivo roles for E2Fs in differentiation and development. Cell Cycle (2007) 6(23):2917-27. doi:10.4161/cc.6.23.4997.
47. Moberg K, Starz MA, Lees JA. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol (1996) 16(4):1436-49.
48. Hurford RK Jr, Cobrinik D, Lee MH, Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev (1997) 11(11):1447-63. doi:10.1101/gad.11.11.1447.
49. Condorelli GL, Testa U, Valtieri M, Vitelli L, De Luca A, Barberi T, et al. Modulation of retinoblastoma gene in normal adult hematopoiesis: peak expression and functional role in advanced erythroid differentiation. Proc Natl Acad Sci U S A (1995) 92(11):4808-12. doi:10.1073/pnas.92.11.4808.
50. Khidr L, Chen PL. RB, the conductor that orchestrates life, death and differentiation. Oncogene (2006) 25(38):5210-9. doi:10.1038/sj.onc.1209612.
51. Hilgendorf KI, Leshchiner ES, Nedelcu S, Maynard MA, Calo E, Ianari A, et al. The retinoblastoma protein induces apoptosis directly at the mitochondria. Genes Dev (2013) 27(9):1003-15. doi:10.1101/gad.211326.112.
52. Gabellini C, Del Bufalo D, Zupi G. Involvement of RB gene family in tumor angiogenesis. Oncogene (2006) 25(38):5326-32. doi:10.1038/sj.onc.1209631.
53. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O, et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 17(4):376-87. doi:10.1016/j.ccr.2010.01.023.
54. Claudio PP, Stiegler P, Howard CM, Bellan C, Minimo C, Tosi GM, et al. RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. Cancer Res (2001) 61(2):462-8.
55. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol (2002) 3(1):11-20. doi:10.1038/nrm714.
56. Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. Cell (1998) 92(4):463-73. doi:10.1016/S0092-8674(00)80940-X.
57. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (1998) 391(6667):601-5. doi:10.1038/35410.
58. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 391(6667):597-601. doi:10.1038/35404.
59. Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin WG Jr. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 18(6):623-35. doi:10.1016/j.molcel.2005.05.012.
60. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet (2000) 25(3):338-42. doi:10.1038/77124.
61. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, et al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell (1994) 79(1):119-30. doi:10.1016/0092-8674(94)90405-7.
62. Singh P, Coe J, Hong W. A role for retinoblastoma protein in potentiating transcriptional activation by the glucocorticoid receptor. Nature (1995) 374(6522):562-5. doi:10.1038/374562a0.
63. Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature (2001) 412(6846):561-5. doi:10.1038/35087620.
64. Gonzalo S, Blasco MA. Role of Rb family in the epigenetic definition of chromatin. Cell Cycle (2005) 4(6):752-5. doi:10.4161/cc.4.6.1720.
65. Steele-Perkins G, Fang W, Yang XH, Van Gele M, Carling T, Gu J, et al. Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev (2001) 15(17):2250-62. doi:10.1101/gad.870101.
66. Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol (2001) 21(19):6484-94. doi:10.1128/MCB.21.19.6484-6494.2001.
67. Talluri S, Dick FA. Regulation of transcription and chromatin structure by pRB: here, there and everywhere. Cell Cycle (2012) 11(17):3189-98. doi:10.4161/cc.21263.
68. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100(1):57-70. doi:10.1016/S0092-8674(00)81683-9.
69. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013.
70. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, et al. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A (1997) 94(13):6933-8. doi:10.1073/pnas.94.13.6933.
71. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, et al. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res (2000) 60(2):372-82.
72. Ikeda MA, Jakoi L, Nevins JR. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci U S A (1996) 93(8):3215-20. doi:10.1073/pnas.93.8.3215.
73. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, et al. Requirement for a functional Rb-1 gene in murine development. Nature (1992) 359(6393):328-30. doi:10.1038/359328a0.
74. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature (1992) 359(6393):295-300. doi:10.1038/359295a0.
75. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (1992) 359(6393):288-94. doi:10.1038/359288a0.
76. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet (1994) 7(4):480-4. doi:10.1038/ng0894-480.
77. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene (1994) 9(4):1021-7.
78. Harrison DJ, Hooper ML, Armstrong JF, Clarke AR. Effects of heterozygosity for the Rb-1t19neo allele in the mouse. Oncogene (1995) 10(8):1615-20.
79. Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, et al. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev (1996) 10(13):1621-32. doi:10.1101/gad.10.13.1621.
80. Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, et al. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev (1996) 10(13):1633-44. doi:10.1101/gad.10.13.1633.
81. Ruiz S, Segrelles C, Bravo A, Santos M, Perez P, Leis H, et al. Abnormal epidermal differentiation and impaired epithelial-mesenchymal tissue interactions in mice lacking the retinoblastoma relatives p107 and p130. Development (2003) 130(11):2341-53. doi:10.1242/dev.00453.
82. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell (1996) 85(4):549-61. doi:10.1016/S0092-8674(00)81255-6.
83. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell (1996) 85(4):537-48. doi:10.1016/S0092-8674(00)81254-4.
84. Yamasaki L. Growth regulation by the E2F and DP transcription factor families. Results Probl Cell Differ (1998) 22:199-227.
85. Murga M, Fernandez-Capetillo O, Field SJ, Moreno B, Borlado LR, Fujiwara Y, et al. Mutation of E2F2 in mice causes enhanced T lymphocyte proliferation, leading to the development of autoimmunity. Immunity (2001) 15(6):959-70. doi:10.1016/S1074-7613(01)00254-0.
86. Humbert PO, Verona R, Trimarchi JM, Rogers C, Dandapani S, Lees JA. E2f3 is critical for normal cellular proliferation. Genes Dev (2000) 14(6):690-703.
87. Cloud JE, Rogers C, Reza TL, Ziebold U, Stone JR, Picard MH, et al. Mutant mouse models reveal the relative roles of E2F1 and E2F3 in vivo. Mol Cell Biol (2002) 22(8):2663-72. doi:10.1128/MCB.22.8.2663-2672.2002.
88. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature (2001) 414(6862):457-62. doi:10.1038/35106593.
89. Ziebold U, Lee EY, Bronson RT, Lees JA. E2F3 loss has opposing effects on different pRB-deficient tumors, resulting in suppression of pituitary tumors but metastasis of medullary thyroid carcinomas. Mol Cell Biol (2003) 23(18):6542-52. doi:10.1128/MCB.23.18.6542-6552.2003.
90. Danielian PS, Friesenhahn LB, Faust AM, West JC, Caron AM, Bronson RT, et al. E2f3a and E2f3b make overlapping but different contributions to total E2f3 activity. Oncogene (2008) 27(51):6561-70. doi:10.1038/onc.2008.253.
91. Kohn MJ, Bronson RT, Harlow E, Dyson NJ, Yamasaki L. Dp1 is required for extra-embryonic development. Development (2003) 130(7):1295-305. doi:10.1242/dev.00355.
92. Maandag EC, van der Valk M, Vlaar M, Feltkamp C, O'Brien J, van Roon M, et al. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J (1994) 13(18):4260-8.
93. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, Riele HT. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev (2004) 18(23):2952-62. doi:10.1101/gad.322004.
94. Parisi T, Yuan TL, Faust AM, Caron AM, Bronson R, Lees JA. Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues. Mol Cell Biol (2007) 27(6):2283-93. doi:10.1128/MCB.01854-06.
95. Parisi T, Bronson RT, Lees JA. Inhibition of pituitary tumors in Rb mutant chimeras through E2f4 loss reveals a key suppressive role for the pRB/E2F pathway in urothelium and ganglionic carcinogenesis. Oncogene (2009) 28(4):500-8. doi:10.1038/onc.2008.406.
96. Mulligan G, Jacks T. The retinoblastoma gene family: cousins with overlapping interests. Trends Genet (1998) 14(6):223-9. doi:10.1016/S0168-9525(98)01470-X.
97. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 14(23):3037-50. doi:10.1101/gad.843200.
98. Dannenberg JH, van Rossum A, Schuijff L, te Riele H. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev (2000) 14(23):3051-64. doi:10.1101/gad.847700.
99. Wirt SE, Sage J. p107 in the public eye: an Rb understudy and more. Cell Div (2010) 5:9. doi:10.1186/1747-1028-5-9.
100. Cobrinik D. Regulatory interactions among E2Fs and cell cycle control proteins. Curr Top Microbiol Immunol (1996) 208:31-61.
101. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev (1998) 12(11):1599-609. doi:10.1101/gad.12.11.1599.
102. Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, Dynlacht BD. E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell (2002) 2(6):463-72. doi:10.1016/S1535-6108(02)00207-6.
103. Mulligan GJ, Wong J, Jacks T. p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. Mol Cell Biol (1998) 18(1):206-20.
104. Martinez LA, Chen Y, Fischer SM, Conti CJ. Coordinated changes in cell cycle machinery occur during keratinocyte terminal differentiation. Oncogene (1999) 18(2):397-406. doi:10.1038/sj.onc.1202300.
105. Paramio JM, Lain S, Segrelles C, Lane EB, Jorcano JL. Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation. Oncogene (1998) 17(8):949-57. doi:10.1038/sj.onc.1202031.
106. D'Souza SJ, Pajak A, Balazsi K, Dagnino L. Ca2+ and BMP-6 signaling regulate E2F during epidermal keratinocyte differentiation. J Biol Chem (2001) 276(26):23531-8. doi:10.1074/jbc.M100780200.
107. D'Souza SJ, Vespa A, Murkherjee S, Maher A, Pajak A, Dagnino L. E2F-1 is essential for normal epidermal wound repair. J Biol Chem (2002) 277(12):10626-32. doi:10.1074/jbc.M111956200.
108. Paramio JM, Segrelles C, Casanova ML, Jorcano JL. Opposite functions for E2F1 and E2F4 in human epidermal keratinocyte differentiation. J Biol Chem (2000) 275(52):41219-26. doi:10.1074/jbc.M004973200.
109. Rodriguez-Puebla ML, de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol (2002) 161(2):405-11. doi:10.1016/S0002-9440(10)64196-X.
110. Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML. Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene (2004) 23(10):1863-73. doi:10.1038/sj.onc.1207309.
111. Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M, et al. Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A (2001) 98(23):13312-7. doi:10.1073/pnas.241338598.
112. Paramio JM, Segrelles C, Ruiz S, Martin-Caballero J, Page A, Martinez J, et al. The ink4a/arf tumor suppressors cooperate with p21cip1/waf in the processes of mouse epidermal differentiation, senescence, and carcinogenesis. J Biol Chem (2001) 276(47):44203-11. doi:10.1074/jbc.M105650200.
113. Wang D, Russell J, Xu H, Johnson DG. Deregulated expression of DP1 induces epidermal proliferation and enhances skin carcinogenesis. Mol Carcinog (2001) 31(2):90-100. doi:10.1002/mc.1044.
114. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG. E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol (1999) 19(9):6408-14.
115. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell (2011) 44(4):667-78. doi:10.1016/j.molcel.2011.08.027.
116. Ruiz S, Segrelles C, Santos M, Lara MF, Paramio JM. Functional link between retinoblastoma family of proteins and the Wnt signaling pathway in mouse epidermis. Dev Dyn (2004) 230(3):410-8. doi:10.1002/dvdy.20065.
117. Conklin JF, Baker J, Sage J. The RB family is required for the self-renewal and survival of human embryonic stem cells. Nat Commun (2012) 3:1244. doi:10.1038/ncomms2254.
118. Lorz C, Garcia-Escudero R, Segrelles C, Garin MI, Ariza JM, Santos M, et al. A functional role of RB-dependent pathway in the control of quiescence in adult epidermal stem cells revealed by genomic profiling. Stem Cell Rev (2010) 6(2):162-77. doi:10.1007/s12015-010-9139-0.
119. Ruiz S, Santos M, Lara MF, Segrelles C, Ballestin C, Paramio JM. Unexpected roles for pRb in mouse skin carcinogenesis. Cancer Res (2005) 65(21):9678-86. doi:10.1158/0008-5472.CAN-05-1853.
120. Lara MF, Garcia-Escudero R, Ruiz S, Santos M, Moral M, Martinez-Cruz AB, et al. Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. Mol Carcinog (2008) 47(3):209-21. doi:10.1002/mc.20376.
121. Ruiz S, Santos M, Segrelles C, Leis H, Jorcano JL, Berns A, et al. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development (2004) 131(11):2737-48. doi:10.1242/dev.01148.
122. Lara MF, Santos M, Ruiz S, Segrelles C, Moral M, Martinez-Cruz AB, et al. p107 acts as a tumor suppressor in pRb-deficient epidermis. Mol Carcinog (2008) 47(2):105-13. doi:10.1002/mc.20367.
123. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, Moral M, et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res (2008) 68(3):683-92. doi:10.1158/0008-5472.CAN-07-3049.
124. Saiz-Ladera C, Lara MF, Garin M, Ruiz S, Santos M, Lorz C, et al. p21 suppresses inflammation and tumorigenesis on pRB-deficient stratified epithelia. Oncogene (2013). doi:10.1038/onc.2013.417.
125. Costa C, Santos M, Segrelles C, Duenas M, Lara MF, Agirre X, et al. A novel tumor suppressor network in squamous malignancies. Sci Rep (2012) 2:828. doi:10.1038/srep00828.
126. Costa C, Santos M, Martinez-Fernandez M, Duenas M, Lorz C, Garcia-Escudero R, et al. E2F1 loss induces spontaneous tumour development in Rb-deficient epidermis. Oncogene (2013) 32(24):2937-51. doi:10.1038/onc.2012.316.
127. Balsitis SJ, Sage J, Duensing S, Munger K, Jacks T, Lambert PF. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. Mol Cell Biol (2003) 23(24):9094-103. doi:10.1128/MCB.23.24.9094-9103.2003.
128. Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL, et al. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 63(13):3716-23.
129. Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, Orlando S, et al. p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene (2012) 31(38):4207-20. doi:10.1038/onc.2011.582.
130. Ruiz S, Santos M, Paramio JM. Is the loss of pRb essential for the mouse skin carcinogenesis? Cell Cycle (2006) 5(6):625-9. doi:10.4161/cc.5.6.2580.
131. Santos M, Ruiz S, Lara MF, Segrelles C, Moral M, Martinez-Cruz AB, et al. Susceptibility of pRb-deficient epidermis to chemical skin carcinogenesis is dependent on the p107 allele dosage. Mol Carcinog (2008) 47(11):815-21. doi:10.1002/mc.20426.
132. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet (1994) 8(1):66-9. doi:10.1038/ng0994-66.
133. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell (1993) 74(5):813-22. doi:10.1016/0092-8674(93)90461-X.
134. Wang NP, To H, Lee WH, Lee EY. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene (1993) 8(2):279-88.
135. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (1994) 371(6492):72-4. doi:10.1038/371072a0.
136. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res (1995) 55(5):1146-51.
137. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev (2000) 14(8):994-1004.
138. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol (2001) 21(6):2144-53. doi:10.1128/MCB.21.6.2144-2153.2001.
139. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, Catalina P, et al. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res (2010) 70(10):4185-94. doi:10.1158/0008-5472.CAN-09-4640.
140. Martinez-Cruz AB, Santos M, Garcia-Escudero R, Moral M, Segrelles C, Lorz C, et al. Spontaneous tumor formation in Trp53-deficient epidermis mediated by chromosomal instability and inflammation. Anticancer Res (2009) 29(8):3035-42.
141. Garcia-Escudero R, Martinez-Cruz AB, Santos M, Lorz C, Segrelles C, Garaulet G, et al. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy. Mol Cancer (2010) 9:193. doi:10.1186/1476-4598-9-193.
142. Duenas M, Santos M, Aranda JF, Bielza C, Martinez-Cruz AB, Lorz C, et al. Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes. PLoS One (2012) 7(8):e42494. doi:10.1371/journal.pone.0042494.
143. Bornachea O, Santos M, Martinez-Cruz AB, Garcia-Escudero R, Duenas M, Costa C, et al. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep (2012) 2:434. doi:10.1038/srep00434.
144. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, et al. miR-17 ~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev (2011) 25(16):1734-45. doi:10.1101/gad.17027411.
145. Marzi MJ, Puggioni EM, Dall'Olio V, Bucci G, Bernard L, Bianchi F, et al. Differentiation-associated microRNAs antagonize the Rb-E2F pathway to restrict proliferation. J Cell Biol (2012) 199(1):77-95. doi:10.1083/jcb.201206033.
146. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75(4):817-25. doi:10.1016/0092-8674(93)90500-P.
147. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature (1993) 366(6456):701-4. doi:10.1038/366701a0.
148. Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol (1998) 141(2):503-14. doi:10.1083/jcb.141.2.503.
149. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A (1999) 96(3):1002-7. doi:10.1073/pnas.96.3.1002.
150. Dimri GP, Nakanishi M, Desprez PY, Smith JR, Campisi J. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol (1996) 16(6):2987-97.
151. Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene (1999) 18(33):4689-98. doi:10.1038/sj.onc.1202840.
152. Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP. p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Natl Acad Sci U S A (1999) 96(16):9089-94. doi:10.1073/pnas.96.16.9089.
153. Weinberg WC, Fernandez-Salas E, Morgan DL, Shalizi A, Mirosh E, Stanulis E, et al. Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res (1999) 59(9):2050-4.
154. Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev (1996) 10(23):3065-75. doi:10.1101/gad.10.23.3065.
155. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta (2000) 1471(1):M43-56.
156. Devgan V, Nguyen BC, Oh H, Dotto GP. p21Waf1/Cip1 suppresses keratinocyte differentiation independently of the cell cycle through transcriptional upregulation of the IGF-1 gene. J Biol Chem (2006) 281(41):30463-70. doi:10.1074/jbc.M604684200.
157. Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK, et al. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science (1998) 280(5366):1069-72. doi:10.1126/science.280.5366.1069.
158. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature (2003) 424(6945):223-8. doi:10.1038/nature01764.
159. Paramio JM, Navarro M, Segrelles C, Gomez-Casero E, Jorcano JL. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene (1999) 18(52):7462-8. doi:10.1038/sj.onc.1203151.
160. Shin MK, Pitot HC, Lambert PF. Pocket proteins suppress head and neck cancer. Cancer Res (2012) 72(5):1280-9. doi:10.1158/0008-5472.CAN-11-2833.
161. Shin MK, Sage J, Lambert PF. Inactivating all three Rb family pocket proteins is insufficient to initiate cervical cancer. Cancer Res (2012) 72(20):5418-27. doi:10.1158/0008-5472.CAN-12-2083.
162. Johnson DG, Cress WD, Jakoi L, Nevins JR. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci U S A (1994) 91(26):12823-7. doi:10.1073/pnas.91.26.12823.
163. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature (1993) 365(6444):349-52. doi:10.1038/365349a0.
164. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res (2004) 2(4):203-14.
165. Nahle Z, Polakoff J, Davuluri RV, McCurrach ME, Jacobson MD, Narita M, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 4(11):859-64. doi:10.1038/ncb868.
166. Pierce AM, Fisher SM, Conti CJ, Johnson DG. Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene (1998) 16(10):1267-76. doi:10.1038/sj.onc.1201666.
167. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A (1998) 95(15):8858-63. doi:10.1073/pnas.95.15.8858.
168. Wikonkal NM, Remenyik E, Knezevic D, Zhang W, Liu M, Zhao H, et al. Inactivating E2f1 reverts apoptosis resistance and cancer sensitivity in Trp53-deficient mice. Nat Cell Biol (2003) 5(7):655-60. doi:10.1038/ncb1001.
169. Russell JL, Weaks RL, Berton TR, Johnson DG. E2F1 suppresses skin carcinogenesis via the ARF-p53 pathway. Oncogene (2006) 25(6):867-76. doi:10.1038/sj.onc.1209120.
170. Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(±)mice. Nat Genet (1998) 18(4):360-4. doi:10.1038/ng0498-360.
171. Tsai KY, Hu Y, MacLeod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell (1998) 2(3):293-304. doi:10.1016/S1097-2765(00)80274-9.